IDC Recommends Open Offer in Bliss GVS Pharma Limited at INR 299 Per Share
The Committee of Independent Directors (IDC) of Bliss GVS Pharma Limited has recommended that public shareholders consider an open offer made by Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited. The recommendation focuses on the fairness and reasonableness of the offer price set against recent market performance.The open offer pertains to the acquisition of a significant stake in Bliss GVS Pharma Limited, with the IDC noting that the proposal was triggered following the proposed acquisition of 4,58,03,024 Equity Shares, representing 26.00% of the Expanded Voting Share Capital (Offer Size).
The offer details are as follows:
| Detail | Description |
|---|---|
| Target Company | Bliss GVS Pharma Limited |
| Acquirer & PAC | Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited |
| Offer Price | INR 299.00 per Offer Share |
| Offer Size | Up to 2,77,26,848 Equity Shares (26.00% of Expanded Voting Share Capital) |
| Total Consideration | INR 829,03,27,552.00 |
The IDC reviewed the relevant documents, including the Public Announcement dated May 23, 2026, and the subsequent Letter of Offer dated July 18, 2026. The Committee members noted that all are Independent Directors of Bliss GVS Pharma Limited, with Mr. Nandkumar Kashinath Chodankar, Chairperson of the IDC, holding 250 Equity Shares of the Target Company as on the date of the recommendation.
Pricing Assessment and Market Comparison
The IDC assessed the Open Offer price of INR 299.00 per Offer Share against established pricing parameters and market trading levels. The Committee determined that the offer price appears fair and reasonable from the perspective of the regulatory pricing framework governing the Open Offer. This finding was based on a review which compared the offer details to the volume weighted average market price (VWAP) and the highest negotiated price under the Share Purchase Agreement.
The IDC also highlighted the stock performance of Bliss GVS Pharma Limited in the period preceding the Letter of Offer. On Friday, July 17, 2026—the trading day immediately preceding the offer date—the company’s Equity Shares closed at:
| Stock Exchange | Closing Price (INR) |
|---|---|
| BSE | 482.50 |
| NSE | 483.50 |
The IDC concluded that the Open Offer is being made at a price of INR 299.00 per Offer Share, despite the closing market prices on July 17, 2026, being higher than the offer price.
Recommendation to Shareholders
Based on its review of all available information and documents, the IDC unanimously recommended that Public Shareholders consider the Open Offer. The Committee advised shareholders to independently evaluate the terms and conditions of the Open Offer, along with their individual investment objectives and financial risk factors before making an informed decision regarding tendering their Equity Shares.
BLISSGVS Stock Price Movement
Shares of Bliss GVS Pharma Limited slipped by 4.36% on Wednesday, settling at ₹448.1 after shedding ₹20.40 from the previous close. The stock traded a total volume of 488,374 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.